

## Scientific Poster Presentations II

Sunday, April 26, 2009

8:00 a.m. – 9:30 a.m.

Rosen Centre – Grand Ballroom

### ENCORE PRESENTATIONS:

Abstracts marked with an “E” are Encore Presentations. Encore presentations undergo the same peer review process as all other presentations, but they may have been presented elsewhere or published in abstract form prior to the 2009 ACCP/ESCP International Congress.

### FINALISTS IN ABSTRACT AWARDS COMPETITION:

Abstracts marked with an “F” are finalists for the Best Paper and Best Resident and Fellow awards. These papers were selected by a special panel of reviewers. The Best Resident and Fellow Poster will be announced at 9:15 a.m., Sunday, April 26, in the Grand Ballroom of the Rosen Centre. The Best Paper will be announced at 10:15 a.m., Tuesday, April 28, during the Final Plenary Session.

### ORIGINAL RESEARCH

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

#### ADR/Drug Interactions

1. Use of oral and intravenous N-acetylcysteine for prevention of contrast-induced nephropathy in a Singapore hospital.  
*Candice Yong, BScPharm(Hons)*, Ian Wee, MPharm(Clin Pharm), Michelle See, BScPharm(Hons); Department of Pharmacy, Changi General Hospital, Singapore, Singapore

#### Adult Medicine

2. Financial impact of venous thromboembolism prophylaxis strategy on costs associated with heparin induced thrombocytopenia: A Monte Carlo simulation.  
*Eli N. Deal, Pharm.D.*, James M. Hollands, Pharm.D., Angela R. Wills, Pharm.D., Lee P. Skrupky, Pharm.D., Scott T. Micek, Pharm.D.; Barnes Jewish Hospital, Saint Louis, MO

#### Ambulatory Care

3. Cardiometabolic risk factor knowledge of participants in a worksite health screening.  
*Amy M. Franks, Pharm.D.*, T. Scott Warmack, Pharm.D., Donna S. West, Ph.D.; University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR
4. Comparison of safety outcomes in three models of anticoagulation management.  
*Kelly M. Rudd, Pharm.D.*, BCPS; Bassett Healthcare, Cooperstown, NY
5. Warfarin therapy in atrial fibrillation: a comparison between established and new patients.  
*Julie M. Sease, Pharm, D*, S. Scott Sutton, Pharm D; South Carolina College of Pharmacy, Columbia, SC
6. Evaluation of guideline adherence for the treatment of asthma in family medicine clinics.  
*Sandra L. Kim, PharmD*, Mitzi Wasik, PharmD, BCPS, Marlowe Djuric, PharmD, Kristen L. Goliak, PharmD, Seema Patel, PharmD, Lori A. Wilken, PharmD, CDE, AE-C, Leslie A. Briars, PharmD, Louise Parent-Stevens, PharmD, BCPS; University of Illinois at Chicago, Chicago, IL
7. Evaluation of antihypertensive medication adherence and intensity of treatment in the Improving Blood Pressure in Colorado Hypertension study.  
*Lesley K. Welch, PharmD<sup>1</sup>*, Kari L. Olson, PharmD<sup>2</sup>, Karen Snow, PharmD<sup>3</sup>, Mary E. Plomondon, PhD<sup>1</sup>, Anne Lambert-Kerzner, MSPH<sup>3</sup>, David W. Brand, MSPH<sup>2</sup>, Edward P. Havranek, MD<sup>3</sup>, David J. Magid, MD, MPH<sup>2</sup>, P. Michael Ho, MD,

PhD<sup>1</sup>; (1)Denver VA Medical Center, Denver, CO; (2)Kaiser Permanente Colorado Region, Aurora, CO; (3)Denver Health Medical Center, Denver, CO

## Cardiovascular

9F. Rebound in thrombotic potential while on clopidogrel therapy.

*Nicholas B. Norgard, Pharm.D.*<sup>1</sup>, Shoaib Saya, M.D.<sup>2</sup>, Eliot Schechter, M.D.<sup>2</sup>, George L. Dale, Ph.D.<sup>2</sup>; (1)University at Buffalo- School of Pharmacy and Pharmaceutical Science, Buffalo, NY; (2)University of Oklahoma Health Sciences Center, Department of Medicine, Oklahoma City, OK

10E. Combination of Angiotensin-receptor blocker, Calcium-channel blocker and Diuretic is Safe and Effective in the Management of Severe Hypertension in Blacks.

John Flack, MD, MPH<sup>1</sup>, David Calhoun, MD<sup>2</sup>, Lisa Satlin, MS, RD<sup>3</sup>, Michaela Barbier, PhD<sup>4</sup>, Patrick Brunel, MD<sup>4</sup>, *Robert Hilker, MD, FACC*<sup>3</sup>; (1)Wayne State University School of Medicine, Detroit, MI; (2)University of Alabama at Birmingham, Birmingham, AL; (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (4)Novartis Pharma AG, Switzerland

## Community Pharmacy Practice

12. Over-the-counter medicines and the patient: distribution and services in Flemish community pharmacy.

*Steven RA Simoens, MSc, PhD*<sup>1</sup>, Marieke Lobeau, PharmD<sup>2</sup>, Koen Verbeke, PharmD, PhD<sup>3</sup>, Arthur van Aerschot, PharmD, PhD<sup>1</sup>; (1)Katholieke Universiteit Leuven, Leuven, Belgium; (2)Royal Pharmaceutical Society of East-Flanders, Ghent, Belgium; (3)Pharmaceutical Society of Bruges and Ostend, Bruges, Belgium

13. Prevalence of Drug-Related Problems in Self-medication (OTC Use).

*Nina Griese, Ph.D.*, Karin Berger, RPh, MPH, Christiane Eickhoff, Ph.D., Ralf Goebel, Ph.D., Andrea Haemmerlein, Ph.D., Uta Mueller, Ph.D., MPH, Christiane Sauerwein, RA., Susanne vom Scheidt, RA., Margit Schmidt, RA., Martin Schulz, Ph.D.; Center for Drug Information and Pharmacy Practice (ZAPP), ABDA - Federal Union of German Associations of Pharmacists, Berlin, Germany

14E. The culture of safety: results of a cross-sectional survey of 998 community pharmacists.

*Darren M. Ashcroft, PhD*, Dianne Parker, PhD; School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom

15F. Impact of access to clinical information on community pharmacists' interventions with polymedicated patients: a randomized controlled trial.

*Natacha Beaulieu, B.Pharm., M.Sc.*<sup>1</sup>, Catherine Cellini, B.Pharm., M.Sc.<sup>2</sup>, Amélie Garneau, B.Pharm., M.Sc.<sup>3</sup>, Lyne Lalonde, B.Pharm., PhD<sup>4</sup>, Olivier Turpin-Lavallée, B.Pharm., M.Sc.<sup>3</sup>, Hélène Lachance-Demers, B.Pharm, M.Sc.<sup>3</sup>, Alain Turcotte, MD<sup>3</sup>, Marie-Claude Vanier, B.Pharm., M.Sc.<sup>4</sup>; (1)Pharmacie Jean-François Guévin, Montréal, QC, Canada; (2)Pharmacie Marc Champagne, Montreal, QC, Canada; (3)CSSS de Laval - Cité de la Santé, Laval, QC, Canada; (4)CSSS de Laval - Cité de la Santé et Faculté de pharmacie, Université de Montréal, Montréal, QC, Canada

16. Embarrassment and purchasing of contraceptives: a study of access and provision of information in pharmacies.

*Daniel Ashwood, BA*<sup>1</sup>, Karen Farris, PhD<sup>1</sup>, Anne Bonsall Hoekstra, MA<sup>2</sup>, Mary Losch, PhD<sup>2</sup>; (1)University of Iowa, Iowa City, IA; (2)University of Northern Iowa, Cedar Falls, IA

## Dermatology

19F. Effect of topical insulin on cutaneous wound healing in non-diabetic and acute diabetic rats.

Sule Apikoglu-Rabus, Ph.D.<sup>1</sup>, *Fikret V. Izzettin, Prof.*<sup>1</sup>, Pinar Turan, Ph.D.<sup>2</sup>, Feriha Ercan, Prof.<sup>2</sup>; (1)Marmara University Faculty of Pharmacy, Clinical Pharmacy Department, Istanbul, Turkey; (2)Marmara University Faculty of Medicine, Histology-Embryology Department, Istanbul, Turkey

## Drug Information

20. Extent of Information Desired in patients with major depression: what happens after hospital discharge?.

*Franciska A. Desplenter, PharmD*<sup>1</sup>, Gert Laekeman, Prof., PhD, PharmD<sup>1</sup>, Koen Demyttenaere, Prof. MD.<sup>1</sup>, Vza Psychiatry, PharmD<sup>2</sup>, Steven Simoens, Prof. MSc.<sup>1</sup>; (1)Katholieke Universiteit Leuven, Leuven, Belgium; (2)Flemish Association of Hospital Pharmacists - Psychiatry, Eeklo, Belgium

## Ear Nose Throat

21. Effects of topical verapamil administration on acute tympanic membrane perforation in guinea pigs.

Mert Eken, M.Sc<sup>1</sup>, Fikret Vehbi Izzettin, Prof<sup>1</sup>, Mehmet Eken, Ph.D<sup>2</sup>, Mesut Sancar, Ph.D<sup>1</sup>, *Betül Okuyan, MSc<sup>1</sup>*; (1)Marmara University Faculty of Pharmacy, Clinical Pharmacy Department, Istanbul, Turkey; (2)2nd ENT, Kartal Training and Research Hospital, Istanbul, Turkey

## Education/Training

22. Impact of a continuous professional development program on the counseling practices and attitudes of the pharmacists about emergency contraceptive pills.

*Sule Apikoglu-Rabus, Ph.D.*, Fikret V. Izzettin, Prof.; Marmara University Faculty of Pharmacy, Clinical Pharmacy Department, Istanbul, Turkey

23E. Safer pharmacy practice: a preliminary study of significant event analysis and peer feedback.

Nicholas Bradley, Ph.D<sup>1</sup>, Ailsa Power, MRPharmS Ph.D<sup>2</sup>, Hannah Hesselgreaves, Ph.D<sup>2</sup>, Fiona McMillan, MRPharmS<sup>2</sup>, Paul Bowie, Ph.D<sup>2</sup>, *Rose Marie Parr, MRPharmS, Ph.D<sup>2</sup>*; (1)Postgraduate Medicine, NHS Education for Scotland, Glasgow, United Kingdom; (2)Pharmacy Directorate, NHS Education for Scotland, Glasgow, United Kingdom

24. Educational Interventions to Curb the Inappropriate Use of Acid-Suppressive Agents on a University Hospital Internal Medicine Service.

Amanda D. Osta, MD<sup>1</sup>, Vikas I. Parekh, MD<sup>1</sup>, *Randolph E. Regal, Pharm.D.<sup>2</sup>*; (1)The University of Michigan Health System, Ann Arbor, MI; (2)The University of Michigan Health System and College of Pharmacy, Ann Arbor, MI

25. Impact of an Evidence Based Medicine elective course on student performance on Advanced Pharmacy Practice Experiences.

*Aida R. Bickley, PharmD, Candidate<sup>1</sup>*, Catherine E. McAbee, PharmD, Candidate<sup>2</sup>, P. Brandon Bookstaver, PharmD<sup>2</sup>; (1)University of South Carolina College of Pharmacy, Columbia, SC; (2)South Carolina College of Pharmacy-USC Campus, Columbia, SC

27. Interdisciplinary student team training in geriatrics.

*Anne L. Hume, PharmD<sup>1</sup>*, Alicia Curtin, PhD, GNP<sup>2</sup>, Philip G. Clark, ScD<sup>1</sup>; (1)University of Rhode Island, Kingston, RI; (2)Memorial Hospital of Rhode Island, Pawtucket, RI

28. Geriatric pharmacotherapy: an approach to active self-directed learning.

Erica Estus, PharmD, CGP, *Anne Hume, PharmD, FCCP, BCPS*, Norma Owens, PharmD, FCCP, BCPS; University of Rhode Island, Kingston, RI

29. Patient education and health promotion: a bridge between disease and illness.

*Daniela Scala, Pharmacist<sup>1</sup>*, Maria D'Avino, Physician<sup>2</sup>, Santolo Cozzolino, Pharmacist<sup>1</sup>, Antonio Mancini, Pharmacist<sup>1</sup>, Barbara Andria, Pharmacist<sup>1</sup>, Giuseppe Caruso, Physician<sup>2</sup>, Domenico Caruso, Physician<sup>2</sup>; (1)Centre of Biotechnologies, Cardarelli Hospital, Naples, Italy; (2)Centre for the diagnosis and therapy of arterial hypertension, Naples, Italy

30. The development of a therapeutic patient education project: the journey from the idea to the realization.

*Daniela Scala, Pharmacist<sup>1</sup>*, Maria D'Avino, Physician<sup>2</sup>, Santolo Cozzolino, Pharmacist<sup>1</sup>, Antonio Mancini, Pharmacist<sup>1</sup>, Barbara Andria, Pharmacist<sup>1</sup>, Giuseppe Caruso, Physician<sup>2</sup>, Domenico Caruso, Physician<sup>2</sup>; (1)Centre of Biotechnologies, Cardarelli Hospital, Naples, Italy; (2)Caentre for the Diagnosis and Therapy of Arterial Hypertension, Naples, Italy

31. Comparison of student performance on multiple choice questions divided into three cognitive domains using Bloom's Taxonomy.

*Zachary A. Stacy, Pharm.D., BCPS*, Amy M. Tiemeier, Pharm.D., John M. Burke, Pharm.D.; St. Louis College of Pharmacy, St. Louis, MO

## Emergency Medicine

32. The impact of pharmacy education on the use of weight-based fosphenytoin dosing in the emergency department.

*April D. Miller, PharmD<sup>1</sup>*, Carrie S. Wylie, PharmD<sup>2</sup>, Joseph Kohn, PharmD<sup>2</sup>; (1)South Carolina College of Pharmacy-USC Campus, Columbia, SC; (2)Palmetto Health Richland, Columbia, SC

33. Factors associated with adverse drug events in a french emergency department.

*Lucien Roulet, Fellow<sup>1</sup>, Jean-Benoit Hardouin, PhD<sup>2</sup>, Florence Ollivier, PharmD<sup>3</sup>, Gilles Potel, M.D., Ph.D.<sup>4</sup>, Françoise Ballereau, PharmD., Ph.D.<sup>3</sup>, Nathalie Asseray, M.D., Ph.D.<sup>1</sup>*; (1)UPRES EA 38 26, Faculté de Médecine, Nantes, France; (2)EA 4572 "Biostatistics, Clinical Research and Subjective Measures in Health Sciences" - Faculté de Pharmacie, Nantes, France; (3)CHU, MEDQUAL, Nantes; (4)CHU, Emergency department, Nantes

## **Endocrinology**

34E. Exenatide utilization and effectiveness in a health plan population.

*Rolin Wade, RPh, MS<sup>1</sup>, Brock Schroeder, PhD<sup>2</sup>, Ralph Quimbo, MA<sup>1</sup>, Derek Misurski, PhD<sup>3</sup>, Rosalind Fabunmi, PhD<sup>2</sup>, Loretta Nielsen, PhD<sup>2</sup>, Matthew Wintle, MD<sup>2</sup>*; (1)HealthCore, Inc., Wilmington, DE; (2)Amylin Pharmaceuticals, Inc., San Diego, CA; (3)Eli Lilly and Company, Indianapolis, IN

35. Occurrence of Hemoglobin A1c testing during inpatient hospitalization at Wellspan.

*Molly A. Walbrown, Pharm.D., CACP, CDE*; Wellspan Health/York Hospital, York, PA

36. Evaluation of prescribing patterns of sitagliptin based on estimated glomerular filtration rates in two multi specialty practices.

*M. Shawn McFarland, PharmD<sup>1</sup>, Jeffery Tunney, PharmD<sup>1</sup>, Chad Gentry, PharmD<sup>2</sup>, Benjamin N. Gross, Pharm., D.<sup>3</sup>, L. Brian Cross, PharmD<sup>2</sup>*; (1)Alvin C. York Veterans Administration, Murfreesboro, TN; (2)University of Tennessee / Holston Medical Group, Kingsport, TN; (3)University of Tennessee, Kingsport, TN

37. Assessment of quality of diabetes care for type 2 diabetics.

*Sule Apikoglu-Rabus, Ph.D.<sup>1</sup>, Mehmet Hursitoglu, Assist., Prof.<sup>2</sup>, Sami S. Bulgurlu, Ph.D.<sup>3</sup>, Akin Dayan, Ph.D.<sup>3</sup>, Nilcihan Yolcu, Ph.D.<sup>3</sup>, Nuray Gebologlu, RN<sup>3</sup>, Fikret V. Izzettin, Prof.<sup>1</sup>*; (1)Marmara University Faculty of Pharmacy, Clinical Pharmacy Department, Istanbul, Turkey; (2)Vakif Gureba Teaching and Research Hospital, Internal Medicine Department, Istanbul, Turkey; (3)Haydarpasa Numune Teaching and Research Hospital, Internal Medicine Department, Istanbul, Turkey

38. Identifying comorbid depression among adults with diabetes in secondary databases.

*Marianne McCollum, PhD, Julia F. Slejko, BS, William V. Padula, MS*; University of Colorado Denver School of Pharmacy, Aurora, CO

## **Ethics in Pharmacy**

39E. A comparative study of the level of agreement with statements on pharmaceutical ethics between interns in France and Quebec.

*Jean-François Bussièrès, B.Pharm, M.Sc.<sup>1</sup>, Karin Scharr, DPharm<sup>1</sup>, Sonia Prot-Labarthe, DPharm<sup>1</sup>, Denis Lebel, B. Pharm, M.Sc.<sup>1</sup>, Olivier Bourdon, DPharm<sup>2</sup>*; (1)CHU Sainte-Justine, Montreal, QC, Canada; (2)APHP hôpital Robert Debré, Paris, France

## **Family Medicine**

40. Survey of physician knowledge regarding acetaminophen dosing, toxicity, and product recognition.

*Lori B. Hornsby, PharmD, Miranda Andrus, PharmD, Jessica Starr, PharmD*; Auburn University Harrison School of Pharmacy, Auburn, AL

## **Gastroenterology**

41. The Role of Lactobacillus in the Prevention of Antibiotic-Associated Diarrhea.

*Pramodini B. Kale-Pradhan, Pharm.D., Sheila M. Wilhelm, PharmD, BCPS, Harjot Jassal, Pharm.D. Candidate, Raymond Cha, Pharm.D.*; Wayne State University, Detroit, MI

42. The effect of arginine and omega 3 fatty acids in critically ill and surgical patients.

*Sheila M. Wilhelm, PharmD, BCPS, Mark Essak, Pharm.D., Candidate, Pramodini B. Kale-Pradhan, Pharm.D., Raymond Cha, Pharm.D.*; Wayne State University, Detroit, MI

## **Geriatrics**

43F. A comprehensive pharmacist intervention to reduce morbidity in patients aged 80 years or older: A randomized, controlled trial

*Ulrika Gillespie, MSc, Pharm<sup>1</sup>* and *Anna Alassaad, MSc, Pharm<sup>2</sup>*

(1)University of Uppsala, Uppsala, Sweden

(2)Hospital pharmacy, Uppsala university hospital, Stockholm, Sweden

## Health Services Research

45E. Helping patients use their medicines more effectively: A pilot study of medicine use reviews in the UK.

*James A. Desborough, MPharm, PhD*, *David J. Wright, BPharm, PhD*, *John Wood, BSc, MSc, BSc*, *Richard C Holland, BA, BM Bch, PhD*; University of East Anglia, Norwich, United Kingdom

46. Identification of resources to provide appropriate language services for Limited English Proficient patients.

*Priti N. Patel, PharmD, BCPS*, *Emily M. Ambizas, PharmD*; St. John's University, Queens, NY

47E. Pre- vs. Post-National Coverage Determination (NCD) blood utilization and hemoglobin values among Medicare patients treated with erythropoietic-stimulating agents (ESAs) for chemotherapy-induced anemia (CIA).

*Tanya Burton, PhD<sup>1</sup>*, *Kay Larholt, ScD<sup>1</sup>*, *Elizabeth Apgar, MPH<sup>1</sup>*, *Chris Pashos, PhD<sup>1</sup>*, *Brahim Bookhart, MBA, MPH<sup>2</sup>*, *Mitra Corral, MS, MPH<sup>2</sup>*, *Catherine T. Piech, MBA<sup>2</sup>*, *R. Scott McKenzie, MD<sup>2</sup>*; (1)Abt Bio-Pharma Solutions, Inc., Lexington, MA; (2)Centocor Ortho Biotech Services, LLC, Bridgewater, NJ

48. Interest in and knowledgebase of practice based research networks (PBRNs): a survey of Maryland pharmacists.

*Heather B. Congdon, PharmD, CACP, CDE*, *Melissa Kim, PharmD Candidate*; University of Maryland School of Pharmacy, Rockville, MD

49. Montenegro primary care physicians awareness of evidence based medicine – call for a clinical pharmacist intervention?.

*Ivana Ilickovic, MSc<sup>1</sup>*, *Branislava Miljkovic, PhD<sup>2</sup>*, *Sandra Vezmar, PhD<sup>2</sup>*; (1)Pharmaswiss, Podgorica, Yugoslavia; (2)School of pharmacy, University of Belgrade, Belgrade, Yugoslavia

50E. Hypoglycemia and costs in patients newly initiated on exenatide or insulin glargine.

*Rolin Wade, RPh, MS<sup>1</sup>*, *Loretta Nielsen, PhD<sup>2</sup>*, *Rosalind Fabunmi, PhD<sup>2</sup>*, *Ralph Quimbo, MA<sup>1</sup>*, *Brock Schroeder, PhD<sup>2</sup>*, *Marjan Massoudi, PharmD<sup>2</sup>*, *Derek Misurski, PhD<sup>3</sup>*, *Matthew Wintle, MD<sup>2</sup>*; (1)HealthCore, Inc., Wilmington, DE; (2)Amylin Pharmaceuticals, Inc., San Diego, CA; (3)Eli Lilly and Company, Indianapolis, IN

## Hematology/Anticoagulation

55F. Renal dysfunction is associated with reduced warfarin maintenance dose and increased INR instability.

*Megan E. Kleinow, PharmD<sup>1</sup>*, *Jennifer L. Clemente, PharmD<sup>1</sup>*, *Candice L. Garwood, PharmD<sup>2</sup>*, *Peter Whittaker, PhD<sup>3</sup>*;

(1)Detroit Medical Center, Detroit, MI; (2)Wayne State University, Department of Pharmacy Practice, Detroit, MI; (3)Wayne State University School of Medicine, Cardiovascular Research Institute and Dept of Emergency Medicine, Detroit, MI

## Herbal/Complementary Medicine

57. Effects of Nigella Sativa oil on cutaneous wound healing in rats.

*Fikret V. Izzettin, Prof.<sup>1</sup>*, *Yasemin Varol, MSc.<sup>1</sup>*, *Sule Apikoglu-Rabus, Ph.D.<sup>1</sup>*, *Adile Cevikbas, Prof.<sup>2</sup>*; (1)Marmara University Faculty of Pharmacy, Clinical Pharmacy Department, Istanbul, Turkey; (2)Marmara University Faculty of Pharmacy, Pharmaceutical Microbiology Department, Istanbul, Turkey

## HIV/AIDS

59. Lipid lowering effects of rosuvastatin in HIV-infected patients on Highly Active Antiretroviral Therapy.

*Humberto R. Jimenez, Pharm.D., BCPS<sup>1</sup>*, *Stephen Esker, Pharm.D.<sup>2</sup>*, *Alexander Ganetsky, Pharm.D.<sup>2</sup>*, *Jihad Slim, M.D.<sup>1</sup>*;

(1)Saint Michael's Medical Center, Newark, NJ; (2)Bristol-Myers Squibb Company, Plainsboro, NJ

## International Pharmacy Education Affiliations

69E. Survey of US colleges/schools of pharmacy concerning international education and research relationships update: past, present and future.

*Rosalie Sagraves, PharmD<sup>1</sup>*, Bruce Currie, PhD<sup>2</sup>, Joseph Dean, PhD<sup>3</sup>; (1)University of Illinois at Chicago, Naperville, IL; (2)University of California Davis, Davis, CA; (3)Samford University, Birmingham, AL

## Managed Care

70. Prevalence of diabetes in a managed care organization and healthcare resource utilization in patients with diabetes and hemoglobin A1c above goal.

*S. Scott Sutton, Pharm.D.*, Julie M. Sease, Pharm, D; South Carolina College of Pharmacy, Columbia, SC

71. Mortality, lipid monitoring, and therapeutic control of patients coded for myocardial infarction within the past five years and seen at least once in a primary care clinic.

*Julie M. Sease, Pharm, D*, S. Scott Sutton, Pharm D; South Carolina College of Pharmacy, Columbia, SC

## Medication Safety

73E. EDUCATIONAL needs arising from PATIENT SAFETY INCIDENT REPORTS related to the use of medicines.

*Rose Marie Parr, PhD*, Hannah Hesselgreaves, PhD, Anne Watson, MSc MED; NHS Education for Scotland, Glasgow

74E. Identifying, understanding, and overcoming barriers to medication error reporting in hospitals in Nova Scotia, Canada.

*Nicole R. Hartnell, MSc<sup>1</sup>*, Neil J MacKinnon, PhD, FCSHP<sup>1</sup>, Ingrid Sketris, PharmD, MPA (HSA)<sup>1</sup>, Steven M. Smith, PhD<sup>2</sup>; (1)Dalhousie University, Halifax, NS, Canada; (2)St. Mary's University, Halifax, NS, Canada

75. Latent opportunities for errors in medication orders in four health authorities

*Neil J. MacKinnon, BSc(Pharm), MSc, PhD<sup>1</sup>*, Rumi Pattar, BSc(Pharm), PharmD<sup>2</sup>, Rita Nigam, PhD<sup>1</sup>, Vaneeta K. Grover, MSc<sup>1</sup> and Tiffany T. Nguyen, BSc<sup>1</sup>

(1)Dalhousie University, Halifax, NS, Canada

(2)University of British Columbia, Vancouver, BC

77. Assessing anticoagulation knowledge in patients new to warfarin therapy.

*Amanda R. McFee, PharmD<sup>1</sup>*, Kelly M. Rudd, PharmD, BCPS<sup>1</sup>, Darren M. Triller, PharmD<sup>2</sup>; (1)Bassett Healthcare, Cooperstown, NY; (2)IPRO, Albany, NY

78. Attitudes of hospital pharmacists to reporting medication errors: insights from focus groups.

*Steven D. Williams, BPharm*, Darren M. Ashcroft, PhD; School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom

79E. Examining patient safety climate in the hospital pharmacy setting: a cross sectional survey.

*Steven D. Williams, BPharm*, Darren M. Ashcroft, PhD; School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom

80. MONOCLONAL antibodies in clinical trials: where reconstitute them for a safety use?.

*Elodie Ostojski, Resident*, Berenice Des Champs, Pharmacist, Christophe Berneron, Pharmacist, Beatrice Thielemans, Pharmacist; University hospital, Lille, France

## Nephrology

81. Serum zinc concentrations in patients on maintenance hemodialysis and its relationship with anemia, parathyroid hormone concentrations and pruritus severity.

*Simin Dashti-Khavidaki, Assistant, Professor*, Hossein Khalili, Associate, Professor, Maryam Vahedi, Pharm D; Tehran University of Medical Sciences, Tehran, Iran

82. The evaluation of Gabapentin therapy for pruritus in the Iranian hemodialysis patients.

*Seyed Mojtaba Sohrevardi, Pharm, D.*, BCPS<sup>1</sup>, Jalal Azmandian, MD, nephrologist<sup>2</sup>; (1)Faculty of pharmacy, yazd medical university, Yazd, Iran; (2)Faculty of medicine, Kerman, Iran

## Neurology

83E. Effect of Caffeine and Choline on Short-Term Memory.

Jamie L. Kearns, Pharm.D., Vincent J. Giannetti, Ph.D., David A. Johnson, Ph.D.; Duquesne University, Pittsburgh, PA

### Neurosurgery

84. Evaluating venous thromboembolism (VTE) prophylaxis in neurosurgical patients with craniotomy.

*Biljana Popovic, Pharm.D., BCPS, BCNSP<sup>1</sup>, Sheila M. Wilhelm, PharmD, BCPS<sup>2</sup>, Bhattacharya Pratik, MD<sup>1</sup>, Asmita Patel, Pharm.D., Student<sup>2</sup>, Megha Parikh, Pharm.D., Student<sup>2</sup>, Lee Anthony, MD<sup>1</sup>, Guthikonda Murali, MD<sup>1</sup>; (1)Harper University Hospital, Detroit, MI; (2)Wayne State University, Detroit, MI*

### Oncology

85. NUCLEIC acid purine based Tamoxifen-Purine analogues as potential anticancer agents.

*Shashikant Phadtare, Ph.D., Nageswara Kode, Ph.D.; College of Pharmacy, Xavier University of Louisiana, New Orleans, LA*

### Pain Management/Analgesia

86. Opiophobic factors that may contribute to inadequate pain management.

*Mark H. McKenzie, B.S., Candidate<sup>1</sup>, Michael W. McKenzie, Ph.D.<sup>2</sup>, Lynda C. McKenzie, M.Ed.<sup>2</sup>, Carole Kimberlin, Ph.D.<sup>2</sup>; (1)University of Florida, Gainesville, FL; (2)University of Florida College of Pharmacy, Gainesville, FL*

### Pharmacoeconomics/Outcomes

88. Economic evaluation of a pharmacy led disease and medicine management programme for patients with COPD.

*Maher Al-Khdour, BSc., MSc., PhD.<sup>1</sup>, Ashley Murray, PhD<sup>2</sup>, Grainne Crealey, PhD<sup>2</sup>, James McElnay, Professor, FCPP<sup>3</sup>; (1)Queen's University Belfast and Al-Quds University, Jerusalem, Israel; (2)Royal Victoria Hospital, Belfast, United Kingdom; (3)Queen's University Belfast, Belfast, United Kingdom*

89. Effectiveness of amlodipine/valsartan single-pill combination therapy in primary care.

*Joseph E. Biskupiak, PhD, MBA<sup>1</sup>, Diana I Brixner, PhD, RPh<sup>1</sup>, Drew Griffin Levy, PhD<sup>2</sup>, Robert Hilkert, MD<sup>2</sup>; (1)University of Utah College of Pharmacy, Salt Lake City, UT; (2)Novartis Pharmaceutical Corporation, East Hanover, NJ*

91. Costs of cardiovascular disease associated with the use of sunitinib and sorafenib in renal-cell carcinoma.

*Rex W. Force, PharmD, FCCP, BCPS<sup>1</sup>, Kjel A. Johnson, Pharm.D.<sup>2</sup>; (1)Departments of Family Medicine and Pharmacy Practice, Idaho State University and improveRX, LLC, Pocatello, ID; (2)ICORE Healthcare, LLC, Orlando, FL*

### Pharmacoepidemiology

92E. Recombinant activated factor VII utilization patterns and thromboembolic Event incidence in critically ill intensive care unit patients.

*Gretchen M. Brophy, PharmD, James R. Robles, PhD; VCU Medical College of Virginia, Richmond, VA*

93. Medication adherence and the use of different sources of medicine information.

*Jurgita Dauksiene, PhD, student, Raimundas Radziunas, Assoc. Prof., Jonas Grincevicius, PhD; Kaunas Medical University, Kaunas, Lithuania*

94. Who carries meticillin resistant *Staphylococcus aureus* (MRSA) in the community ?.

*Sonia Thibaut, PhD<sup>1</sup>, Jocelyne Caillon, Pharm, D, PhD<sup>2</sup>, Nathalie Asseray, M.D., Ph.D.<sup>2</sup>, Didier Lepelletier, M.D., PhD<sup>2</sup>, Pierre Lombraill, M.D., PhD<sup>1</sup>, Gilles Potel, M.D, PhD<sup>2</sup>, Françoise Ballereau, PharmD., Ph.D.<sup>1</sup>; (1)MedQual, Nantes, France; (2)UPRES EA 38 26, Faculté de Médecine, Nantes, France*

95. Prophylaxis of venous thromboembolism in orthopaedic surgery: impact of regional guidelines.

*Francesca Venturini, Pharm., D., M.S., Andrea Scalvi, M.D., Valeria Biasi, M. Stat., Giovanna Scroccaro, Pharm.D.; Azienda Ospedaliera di Verona, Verona, Italy*

96F. Genetic and clinical determinants of warfarin dose requirements in African Americans.

*Larisa H. Cavallari, Pharm.D., Kathryn M. Momary, Pharm.D., Shital R. Patel, M.S., Nancy L. Shapiro, Pharm.D., Edith A. Nutescu, Pharm.D., Marlos A.G. Viana, Ph.D.; University of Illinois at Chicago College of Pharmacy, Chicago, Illinois USA*

## Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery

97. Pharmacokinetics and Dosing of Desirudin in Moderate Renal Impairment Using Monte Carlo Simulation.

*Joseph S. Bertino Jr., PharmD*, Anne N. Nafziger, MD, PhD; Bertino Consulting, Schenectady, NY

98. Salazar-Corcoran equation versus Cockcroft-Gault formula in antimicrobial dosing in obese patients.

Teena Abraham, B.S., M.S., Pharm.D., BCPS, Steven D. Colby, M.D., Natalya Goldshteyn, M.D., Larry Bernstein, M.D., Nasser Saad, B.S., Pharm.D., Lamy Bakoss, B.S., R.Ph., Eric Balmir, B.S., R.Ph., M.S., *Fabienne Vastey, B.S., Pharm.D.*; New York Methodist Hospital, Brooklyn, NY

99E. Influence of plasma exchange on the disposition of the fourth generation cephalosporin cefepime.

*Rami B. Ibrahim, Pharm.D.<sup>1</sup>*, Simon M. Cronin, Pharm.D.<sup>2</sup>, Chin Liu, Pharm.D.<sup>2</sup>, Raymond Cha, Pharm.D.<sup>3</sup>, Paul Swerdlow, M.D.<sup>4</sup>, Tomoco Avila, R.N.<sup>5</sup>, Stephen T. Smith, M.S.<sup>2</sup>, Richard Lewis, M.D.<sup>6</sup>, David J. Edwards, Pharm.D.<sup>3</sup>; (1)Karmanos Cancer Institute and Eugene Applebaum College of Pharmacy and the School of Medicine, Wayne State University, Detroit, MI; (2)Karmanos Cancer Institute and Eugene Applebaum College of Pharmacy, Wayne State University, Detroit, MI; (3)Eugene Applebaum College of Pharmacy, Wayne State University, Detroit, MI; (4)Karmanos Cancer Institute and the School of Medicine, Wayne State University, Detroit, MI; (5)Karmanos Cancer Institute, Detroit, MI; (6)School of Medicine, Wayne State University, Detroit, MI

100. Clinical utility of the Child-Pugh score to determine hepatic dose adjustments of selected antimicrobials.

*Gina M. DeSevo, Pharm.D.*, Michael A. Wynd, Pharm.D., Arpi G. Kuyumjian, Pharm.D., Cristina E. Cicogna, M.D.; Hackensack University Medical Center, Hackensack, NJ

102. Steady state pharmacokinetics of oral voriconazole and its primary metabolite (UK121-265) pre and post autologous peripheral stem cell transplantation.

*Jarrett R. Amsden, Pharm.D.<sup>1</sup>*, Scott A. McConnell, PharmD<sup>2</sup>, Paul O. Gubbins, Pharm.D.<sup>3</sup>, Elias J. Anaissie, MD<sup>3</sup>; (1)Butler University, Indianapolis, IN; (2)Cubist Pharmaceuticals, Lexington, MA; (3)University of Arkansas for Medical Sciences, Little Rock, AR

103. Comparison of the modification of diet in renal disease study equation to the Cockcroft-Gault equation for estimation of vancomycin troughs.

*Eric Greenberg, Pharm., D.*, Nasser Saad, Pharm. D., Teena Abraham, Pharm. D., Matt Briggs, Ph. D.; New York Methodist Hospital, Brooklyn, NY

104. Protamine dosing in cardiopulmonary bypass procedures: is there a best practice?.

*Eric L. Chernin, BS, Pharmacy*, David W. Jungst, Pharm.D.; Sarasota Memorial Hospital, Sarasota, FL

## Psychiatry

105. CIMS:Concordance In a Mental health Setting.

*Debi Bhattacharya, PhD<sup>1</sup>*, Rebecca Inglis, MPharm<sup>1</sup>, Ansuya Solanki, MPharm<sup>1</sup>, Savaan Nathwani, MPharm<sup>1</sup>, John Hunter, MSc, DipEBP<sup>2</sup>; (1)University of East Anglia, Norfolk, United Kingdom; (2)Norfolk and Waveney Mental Health NHS Foundation Trust, Norfolk, United Kingdom

## Pulmonary

106F. Design and validation of a Medication Assessment Tool (MAT) to evaluate the quality of medication use based on international guidelines of asthma management in children aged from 5 to 12 years.

*Hui-Ping Liu, MSc<sup>1</sup>*, You-Mei Lin, MS<sup>2</sup>, Steve Hudson, Professor<sup>3</sup>, Julienne Johnson, BPharm, MSc, PhD, MRPharmS<sup>4</sup>, Hsiu-Yu Chien, MS<sup>2</sup>; (1)Department of Pharmacy, Taipei Medical University-Shuang Ho Hospital, Jhonghe City, Taipei County, Taiwan; (2)1. Taipei Medical University, 2. Department of Pharmacy, Taipei Medical University-Shuang Ho Hospital, Jhonghe City, Taipei County, Taiwan; (3)Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0NR, United Kingdom; (4)Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom

107F. A prospective assessment of therapeutic efficacy and immune effects of levofloxacin and ofloxacin in multiple-drug resistant tuberculosis.

*Philip M. Clark, Assist., Prof.*<sup>1</sup>, *Sule Apikoglu-Rabus, Ph.D.*<sup>2</sup>, *Bayram Kiran, Assist., Prof.*<sup>3</sup>, *Turan Karagoz, Associate, Prof.*<sup>4</sup>, *Fikret V. Izzettin, Prof.*<sup>2</sup>; (1)Yeditepe University Department of Pharmacy, Istanbul, Turkey; (2)Marmara University Faculty of Pharmacy, Clinical Pharmacy Department, Istanbul, Turkey; (3)Istanbul University, Istanbul Medical Faculty - Department of Microbiology Virology and Basic Immunology, Istanbul, Turkey; (4)Sureyyapasa Center for Chest Diseases and Thoracic Surgery, Istanbul, Turkey

108E. Impact of Uncontrolled Asthma on School Attendance and Social Functioning Among Pediatric Patients.

*Bonnie Dean, PhD*<sup>1</sup>, *Brian Calimlim, MS*<sup>1</sup>, *Daniel Aguilar, MPH*<sup>1</sup>, *Patricia Sacco, MPH*<sup>2</sup>, *Robert Maykut, MD*<sup>2</sup>, *David Tinkelman, MD*<sup>3</sup>; (1)Cerner LifeSciences, Beverly Hills, CA; (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (3)National Jewish Medical and Research Center, Denver, CO

109E. Demographic and Clinical Factors Associated with Poor Asthma Control in Patients With Severe or Difficult-to-Treat Asthma.

*Tmirah Haselkorn, PhD*<sup>1</sup>, *James E. Fish, MD*<sup>2</sup>, *Larry Borish, MD*<sup>3</sup>, *David R. Mink, MD*<sup>4</sup>, *Hubert Chen, MD, MPH*<sup>5</sup>, *Sally E. Wenzel, MD*<sup>6</sup>; (1)EpiMetrix Inc, Sunnyvale, CA; (2)Genentech Inc, South San Francisco, CA; (3)University of Virginia Health Systems, Charlottesville, VA; (4)ICON Clinical Research, San Francisco, CA; (5)University of California - San Francisco, San Francisco, CA; (6)University of Pittsburgh, Pittsburgh, PA

## **Substance Abuse/Toxicology**

110. An observational study of intentional drug overdoses in a Singapore hospital.

*Ian Wee, MPharm(ClinPharm)*<sup>1</sup>, *Chai Ling Ong, BSc(Pharm)(Hons)*<sup>2</sup>, *Charlene Ong, BSc(Pharm)(Hons)*<sup>1</sup>; (1)Changi General Hospital, Singapore, Singapore; (2)National Heart Centre, Singapore, Singapore

## **Transplant/Immunology**

111. Review and revision of the clinical practice of G-CSF treatment in patients undergoing autologous and allogeneic hematopoietic stem cell transplantation at UCSD.

*Meghana Trivedi, PharmD, PhD*, *Sue Corringham, RN*, *Sam Martinez, PharmD*, *Edward D. Ball, MD*, *Katherine Medley, PharmD*; University of California, San Diego, La Jolla, CA

114E. In vitro dissolution of mycophenolate mofetil: differences observed between innovator and generic formulations.

*Emmanuel Scheubel, MD*, *Laurent Adamy, PhD*; F. Hoffmann-La Roche Ltd, Basel, Sweden

115F. Effect of genetic polymorphism of MRP2 and UGT2B7 on gastrointestinal symptom rating scale in kidney transplant recipients taking mycophenolic acid.

*Jaewook Yang, Ph.D., Pharm.D*<sup>1</sup>, *Puay-hoon Lee, B.S.*<sup>2</sup>, *Vera Pravica, M.D., Ph.D*<sup>3</sup>, *Ian V. Hutchinson, Ph.D.*<sup>4</sup>, *Tariq Shah, M.D.*<sup>5</sup>, *David I. Min, Pharm.D.*<sup>6</sup>; (1)Western University of Health Sciences, College of Pharmacy and National Institute of Transplantation, Los Angeles, CA; (2)Singapore General Hospital, Singapore, Singapore; (3)USC/National Institute of Transplantation, Los Angeles, CA; (4)USC School of Pharmacy, Los Angeles, CA; (5)St. Vincent Medical Center and National Institute of Transplantation, Los Angeles, CA; (6)Western University of Health Sciences, College of Pharmacy and National Institute of Transplantation, Los Angeles, CO

## **Urology**

116. Effect of multiple doses of the cytochrome CYP3A4 inhibitor ketoconazole on the single-dose pharmacokinetics of the highly selective alpha-1A-adrenoceptor antagonist silodosin in healthy men.

*Lawrence A. Hill, PharmD*, *Weining Volinn, MS*, *Gary Hoel, RPh, PhD*; Watson Laboratories, Salt Lake City, UT

117. Maximum tolerated dose of silodosin, a highly selective alpha-1A-adrenoceptor antagonist, for the treatment of symptoms associated with benign prostatic hyperplasia.

*Lawrence A. Hill, PharmD*, *Weining Volinn, MS*, *Gary Hoel, RPh, PhD*; Watson Laboratories, Salt Lake City, UT

118. Effect of renal impairment on plasma concentrations of silodosin and its main metabolites in patients with symptoms of benign prostatic hyperplasia.

*Leonard S. Marks, MD*<sup>1</sup>, *Marc A. Gittelman, MD*<sup>2</sup>, *Lawrence A. Hill, PharmD*<sup>3</sup>, *Weining Volinn, MS*<sup>3</sup>, *Gary Hoel, RPh, PhD*<sup>3</sup>; (1)University of California Los Angeles, Culver City, CA; (2)South Florida Medical Research, Aventura, FL; (3)Watson Laboratories, Salt Lake City, UT

## Women's Health

119. Thorough QTc (TQT) interval assessment of a novel nonimmediate release oral tranexamic acid product on ventricular repolarization in fasting healthy women.

*Keith A. Moore, PharmD<sup>1</sup>, Timothy S. Callahan, PhD<sup>2</sup>, Pierre Maison-Blanche, MD<sup>2</sup>, Isabelle Morin, BSc<sup>3</sup>, Ted Marengo, MSc<sup>3</sup>; (1)Xanodyne Pharmaceuticals, Inc, Newport, KY; (2)Biomedical Systems, Inc, St. Louis, MO; (3)MDS Pharma Services, Montreal, QC, Canada*

## CLINICAL PHARMACY FORUM

These abstracts describe the delivery, development, justification, or documentation of innovative clinical pharmacy services; they may be descriptive only and need not contain an evaluative component.

## Adult Medicine

120. Implementation of the Follow Me Home Medication Reconciliation Program (FMHMRP).

*Manoukhathe Cassagnol, Pharm.D., CGP<sup>1</sup>, Danielle Ezzo, Pharm.D., BCPS, CGP<sup>1</sup>, Emily Ambizas, Pharm.D. <sup>1</sup>, Maha Saad, Pharm.D., BCPS, CGP<sup>1</sup>, Martin Lesser, PhD<sup>2</sup>, Harold Steinberg, MD<sup>3</sup>; (1)St. John's University, Queens, NY; (2)Long Island Jewish Medical, New Hyde Park, NY; (3)Long Island Jewish Medical Canter, New Hyde Park, NY*

## Ambulatory Care

121. Is there a correlation between patient's knowledge of hypertension and blood pressure control?.

*Eunice P. Chung, Pharm.D., Jadie C. Trinh, Pharm.D., Jeany K Jun, Pharm.D., Alan D Cundari, D.O.; Western University of Health Sciences, College of Pharmacy, Pomona, CA*

122. Evaluating patient satisfaction of e-mail communication to improve blood glucose control in type 2 diabetes mellitus.

*Laura Perry, PharmD<sup>1</sup>, Steve Smith, MS<sup>2</sup>; (1)The University of Findlay, Findlay, OH; (2)The Toledo Hospital Family Medicine Residency, Toledo, OH*

123. Preliminary results of a pharmacist managed oral anticoagulation service at a long-term care facility.

*Haley M. Phillippe, Pharm.D<sup>1</sup>, Joyce V. Loyed, Pharm.D<sup>2</sup>; (1)Auburn University Harrison School of Pharmacy, Owens Cross Roads, AL; (2)Salem VA Medical Center, Salem, VA*

124. Development of a pharmacist-managed diabetes care clinic in an urban community health center.

*Christine A. Schumacher, Pharm.D.<sup>1</sup>, Kathy E. Fit, Pharm.D., BCPS<sup>2</sup>, Brooke L. Griffin, PharmD<sup>2</sup>, Jill S. Burkiewicz, Pharm.D., BCPS<sup>3</sup>; (1)Midwestern University College of Pharmacy, Downers Grove, IL; (2)Midwestern University Chicago College of Pharmacy, Downers Grove, IL; (3)Midwestern University - Chicago College of Pharmacy, Downers Grove, IL*

125. Medication therapy management: providing clinical pharmacy services to wounded soldiers with psychiatric disorders.

*Laura P. Woods, PharmD, Toby L. Cooper, PharmD, BCPS, Gwendolyn H. Thompson, PharmD, MPA, BCPS, Nancy A. Radebaugh, RPh, Rania S. Kattura, Pharm.D., M.S.Phr; Carl R. Darnall Army Medical Center, Ft Hood, TX*

126. Detecting and assessing cognitive deficits in Hispanics with type 2 diabetes: The role of a clinical pharmacist.

*Joshua Caballero, PharmD<sup>1</sup>, Garry Souffrant, MD<sup>2</sup>; (1)Nova Southeastern University, Fort Lauderdale, FL; (2)Su Clinica Familiar, Harlingen, TX*

127. Health Impact of a Worksite Pharmacist-Directed Wellness Center on Risks for Cardiovascular Disease in an Employee Cohort.

*Jamie L. Kearns, Pharm.D.<sup>1</sup>, Holly C. Lassila, DrPh, RPh<sup>1</sup>, Hildegard J. Berdine, Pharm.D., BCPS<sup>2</sup>, Christine K. O'Neil, Pharm.D., BCPS, FCCP<sup>1</sup>, Bruce Livengood, Pharm.D.<sup>1</sup>; (1)Duquesne University, Pittsburgh, PA; (2)Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA*

128. Effectiveness of a collaborative lipid clinic developed in an academic heart hospital ambulatory care clinic.

*Margueritte Hevezi, PharmD, Scott Merryman, MD, Vasudevan Raghavan, MBBS, MD, MRCP, (UK), Trisha Jordan, PharmD, MS, Melissa Snider, PharmD; The Ohio State University Ross Heart Hospital, Columbus, OH*

129. Pharmacist-Physician Collaborative Management In Optimising Antihypertensive Therapy for Chronic Kidney Disease Patients.

*Yee Ming Lee, MPharmSci*, Lee Ying Yeoh, MBBS, Su Chi Lim, MBBS, Chee Fang Sum, MBBS, Tavintharan Subramaniam, MBBS, Ling Choo Lim, MBBS; Alexandra Hospital, Singapore, Singapore

130. Black Education and Treatment of Hypertension Trial.

*Stephanie Maciejewski, Pharm.D.*, Robyn M. Kondrack, Pharm.D., Daniel E. Hilleman, PharmD, Shavonne Washington-Krauth, BSEd, Syed M. Mohiuddin, MD; The Cardiac Center of Creighton University, Omaha, NE

131. Establishing ambulatory care clinical pharmacy services in a free clinic through community engagement.

*Sallie D. Mayer, PharmD, MBA, BCPS*, Daniel Cole Kildow, PharmD, Evan M. Sisson, PharmD, MHA, Brigitte L. Sicut, PharmD, Daniel E. Carl, MD; Virginia Commonwealth University School of Pharmacy, Richmond, VA

## **Clinical Administration**

134. Impact of a natural disaster on the practice of pharmacy: the reaction of pharmacists and other stakeholders directly and indirectly involved.

*Susan H. Staggs, PharmD<sup>1</sup>*, Kate Puetz, Pharm.D.<sup>2</sup>, Jordan F. Baye, Student Pharmacist<sup>1</sup>; (1)University of Iowa, Iowa City, IA; (2)Iowa Pharmacy Association, Des Moines, IA

136E. Importing unlicensed medicines in a Portuguese University Hospital.

*Ana Rita Lopes, Pharm, D*, Ana Cristina Rama, Pharma, D, Abreu Adelaide, Pharma, D, Maria Jose Saraiva, Pharma, D, Adelaide Lima, Pharma, D, Paula Pina, Pharma, D, Rita Joao Lopes, Pharma, D, Sebastiao Ferreira da Silva, Pharma, D, Jose Feio, Pharma, D, Odete Isabel, Pharma D, Francisco Machado, Pharm D; HUC, Coimbra, Portugal

## **Clinical Pharmacy**

137. The Pharmaceutical Intervention in a Cardiology and Pulmonology Wards.

*Ana G. Parola, Pharmacist*, Maria Helena Farinha, Pharm D., Maria de Fátima Falcão, Pharm D.; Pharmaceutical Services – Hospital de Egas Moniz, Hospital Centre Lisbon West, Lisboa, Portugal

## **Clinical trials**

138. The hospital pharmacist in clinical trials.

*Francisco Machado, Pharmcist*, Sebastiao Silva, Pharmacist, Jose Feio, Pharmcist, Adelaide Lima, Pharm, D, Paula Pina, Pharm, D, Ana Rita Lopes, Pharm, D, Alexandra Torres, Pharm, D, Angelina Martins, Pharm D; HUC, Coimbra, Portugal

## **Community Pharmacy Practice**

139. From therapeutic innovation to good use : Dibotermine alpha in fracture femur guideline.

*Emmanuelle Cohen De Lara, pharmacist, resident<sup>1</sup>*, Julie Rouprêt-Serzec, pharmacist<sup>1</sup>, Mahamadou Tandia, pharmacist<sup>1</sup>, Marysa Héricourt, technician<sup>1</sup>, Agnès Certain, PH<sup>2</sup>, Philippe Arnaud, pharmacist<sup>1</sup>; (1)Hospital Bichat Claude Bernard, Paris, France; (2)Pharmacy, Hospital Bichat Claude Bernard, Paris, France

140. IMPACT of pharmaceutical evaluation of drug dosage adjustment according to renal function in a cardiology department of university hospital.

*Julie Pouzoulet, PharmD*, Roxana Mohammadi, PharmD, Nisryn Razzouq, PharmD, Muriel Paul, PharmD, Alain Astier, PharmD; Henri Mondor university hospital, Creteil, France

## **Critical Care**

141F. Comparison of tight vs. more liberal blood glucose target ranges in surgical trauma intensive care unit patients.

*Jason S. Haney, Pharm.D.*, Cathy L. Worrall, Pharm.D., BCPS, BCNSP, FAPhA, Kit N. Simpson, DrPH, Stuart M. Leon, M.D.; Medical University of South Carolina, Charleston, SC

## **Education/Training**

148E. Impact of pharmacy students' recommendations during an ambulatory care advanced pharmacy practice experience.

*Lisa M. Lundquist, PharmD, BCPS*; Mercer University, Atlanta, GA

149. Assessment of attitudes and value placed on pharmacist board certification.

*Andrew Smith, Pharm.D.*<sup>1</sup>, Tony Huke, Pharm.D.<sup>2</sup>; (1)UMKC School of Pharmacy, Kansas City, MO; (2)Truman Medical Center, Kansas City, MO

150. Continuing Professional Development: Pharmacist provided smoking cessation brief intervention program.  
*Autumn L. Runyon, PharmD.*, Monica L. Skomo, PharmD, Pamela H. Koerner, PharmD, Christine K. O'Neil, PharmD, FCCP, BCPS, Andrea Reath, PharmD Candidate; Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA

151. Identifying international health experiential opportunities at colleges of pharmacy in the United States.  
*Patricia Klein, PharmD, MPH*<sup>1</sup>, *Patricia R. Wigle, Pharm.D., BCPS*<sup>2</sup>, Matthew J. Brown, PharmD<sup>3</sup>, Katie Clark, Pharm.D.<sup>4</sup>; (1)Drug and Poison Information Center, Cincinnati, OH; (2)University of Cincinnati, Cincinnati, OH; (3)Chillicothe VA Medical Center, Chillicothe, OH; (4)Grant Medical Center, Columbus, OH

152. Could the involvement of pharmacist students improve patients' knowledge about their anticoagulant treatment?.  
*Melanie Brignone, Pharm.D.*<sup>1</sup>, Ornella Conort, Pharm.D., Ph.D.<sup>2</sup>, Sara Nazaraly, MSc<sup>1</sup>, Sandrine Houze, PH, PhD<sup>3</sup>, Agnès Certain, Pharm.D., Ph.D.<sup>4</sup>, Virginie Siguret-Depasse, Pharm.D., PhD<sup>5</sup>, Eric Pautas, Pharm.D.<sup>6</sup>, Françoise Brion, Pharm.D., Ph.D.<sup>5</sup>, Nathalie Pons-Kerjean, Pharm.D.<sup>7</sup>, Olivier Bourdon, Pharm.D., PhD<sup>5</sup>, Patrick Tilleul, Pharm.D., PhD<sup>1</sup>; (1)Pharmacy, Saint-Antoine Hospital, Paris, France; (2)Pharmacy, Cochin Hospital, Paris, France; (3)Parasitology, Bichat Hospital, Paris, France; (4)Pharmacy, Hospital Bichat Claude Bernard, Paris, France; (5)Pharmacy University Paris-Descartes, Paris, France; (6)Hematology, Louis Mourier Hospital, Colombes, France; (7)Pharmacy, Louis Mourier Hospital, Colombes, France

153. Retention of knowledge and confidence level of cardiopulmonary resuscitation learned in a pharmacy skills patient assessment course.  
*Kristi A. Isaac, Pharm.D., AE-C*, Cori M. Brock, Pharm.D., CDE; Xavier University College of Pharmacy, New Orleans, LA

## **Endocrinology**

154F. Differences in cell migration and protease secretion between normal and type-1 diabetic fibroblasts.  
*Kathryn A. Connor, Pharm.D.*<sup>1</sup>, William J. Lindblad, Ph.D.<sup>2</sup>, Mamata Vallury, B.Pharm.<sup>2</sup>, Anjan Kowluru, Ph.D.<sup>2</sup>; (1)The Regional Medical Center at Memphis, Memphis, TN; (2)Wayne State University, Detroit, MI

## **Family Medicine**

155E. Developing a new role of liaison for pharmacists in a family medicine clinic.  
*Marie-Claude Vanier, BPharm, MSc*<sup>1</sup>, H el ene Lachance-Demers, B.Pharm, M.Sc.<sup>2</sup>, Am elie Garneau, B.Pharm., M.Sc.<sup>2</sup>, Catherine Cellini, B, Pharm., M.Sc.<sup>3</sup>, Natacha Beaulieu, M.Sc.<sup>4</sup>, Olivier Turpin-Lavall e, B.Pharm., M.Sc.<sup>2</sup>, Alain Turcotte, MD<sup>2</sup>, Lyne Lalonde, BPharm, PhD<sup>1</sup>; (1)CSSS de Laval - Cit e de la Sant e and Facult e de pharmacie, Universit e de Montr eal, Montr eal, QC, Canada; (2)CSSS de Laval - Cit e de la Sant e, Laval, QC, Canada; (3)Pharmacie Marc Champagne, Montreal, QC, Canada; (4)Pharmacie Jean-Fran ois Gu evin, Montr eal, QC, Canada

## **Gastroenterology**

156. Pantoprasol versus ranitidine in the treatment of gastrointestinal hemorrhage.  
*Gordana D. Vucic, MSc*, Mirjana Kendrisic, MD; Health Centre Sremska Mitrovica, Sremska Mitrovica, Serbia and Montenegro

## **Health Policy**

162. Developing an evidence-based provincial model for remuneration of pharmacist clinical services: policy implications from the perspective of government in British Columbia, Canada.

Elaine Chong, BSc(Pharm), PharmD, BCPS<sup>1</sup>, Ariel Lade, Senior, Economist<sup>2</sup>, Elisheba Muturi, MSc, MLIS, MAS<sup>1</sup>, Regina McGowan, Policy, Analyst<sup>2</sup>, Aileen Mira, BSP, ACPR<sup>1</sup>, Glenda P. MacDonald, BSP, ACPR, PharmD<sup>1</sup>, Sarah Jennings, BSc, BSc(Pharm)<sup>1</sup>, Mitch Moneo, Director, Policy&Communications<sup>2</sup>, Brett Wilmer, Director, Economic, Analysis<sup>2</sup>, Darlene Therrien, Executive Director<sup>2</sup>, Paul Mochrie, Executive, Director<sup>3</sup>, *Suzanne C. Malfair Taylor, BSc(Pharm), PharmD, BCPS, FCSHP*<sup>1</sup>; (1)Drug Use Optimization Branch, Pharmaceutical Services Division, BC Ministry of Health Services, New Westminster, BC, Canada; (2)Policy Outcomes, Evaluation and Research Branch, Pharmaceutical Services Division, Victoria, BC, Canada; (3)Business Management, Supplier Relations and Systems Branch, Pharmaceutical Services Division, BC Ministry of Health Services, New Westminster, BC, Canada

## Infectious Diseases

165F. Relationships between antibiotics usage and nosocomial-acquired Gram-negative bacteria drug resistance: An experience in a medical center at South Taiwan, 2001-2006.

*Chen F. Fangting, master, Chen I. I-Ling, master; Chang Gung Memorial Hospital -Kaohsiung, Kaohsiung, Taiwan*

## Information technology

167. The importance of clinical decision support systems (CDSS) for therapeutic individualization in a computerized physician order entry (CPOE).

*Sebastiao Silva, PharmD<sup>1</sup>, Francisco Machado, PharmD<sup>1</sup>, Jose Feio, PharmD<sup>1</sup>, Artur Rebelo, PharmD<sup>1</sup>, Pedro Costa, Eng<sup>2</sup>, Anabela Heliskowsky, Eng<sup>2</sup>, Orlando Rodrigues, Eng<sup>2</sup>, Rui Janeiro, Dr<sup>1</sup>, Odete Isabel, PharmD<sup>1</sup>; (1)HUC, Coimbra, Portugal; (2)CPC-H, Porto, Portugal*

## Nephrology

172. Impact of pharmacist-initiated interventions in the dialysis unit of a Lebanese tertiary teaching hospital.

*Rony Zeenny, PharmD<sup>1</sup>, Abir Saade, PharmD Candidate<sup>1</sup>, Wael Abi Ghanem, RPh<sup>2</sup>; (1)Lebanese American University, Byblos, Lebanon; (2)Saint Georges Hospital-University Medical Center, Beirut, Lebanon*

## Neurology

173. Guidelines for the use of temozolomide in adult brain tumors treatment in the French context.

*Patrick Tilleul, PH, PhD<sup>1</sup>, Melanie Brignone, PH<sup>1</sup>, Yasmine Hassani, Ms<sup>1</sup>, Luc Taillandier, MD<sup>2</sup>, Sophie Taillibert, MD<sup>3</sup>, Stephanie Cartalat-Carel, MD<sup>4</sup>, Isabelle Borget, PH<sup>5</sup>, Olivier Chinot, MD, PhD<sup>6</sup>; (1)Pharmacy, Saint-Antoine hospital, Paris, France; (2)Neurology, Saint-Julien Hospital, Nancy, France; (3)Neuro-Oncology, La Pitie Salpetriere Hospital, Paris, France; (4)Neurology, Pierre Wertheimer Hospital, Lyon, France; (5)Gustave Roussy Institute, Villejuif, France; (6)Neuro-Oncology, La Timone Hospital, Marseille, France*

## Nutrition

174. Comparison of two types of total parenteral nutrition prescription methods in preterm neonates.

*Maria Skouroliakou, PhD<sup>1</sup>, Katerina Koutri, RD<sup>2</sup>, Maria Stathopoulou, RD<sup>1</sup>, Ekaterini Vourvouhaki, Dr<sup>1</sup>, Ifigenia Giannopoulou, PhD<sup>1</sup>, Antonios Gounaris, MD<sup>3</sup>; (1)Harokopio University, Athens, Greece; (2)Mitera Maternity Hospital, Athens, Greece; (3)General Hospital of Piraeus "Ag. Panteleimon", Piraeus, Greece*

175. Impact of a clinical pharmacist on undernutrition caring.

*Celine M. Michel, MPharm, MSc<sup>1</sup>, Anne Spinewine, MPharm, MSc, PhD<sup>2</sup>, Ariane Mouzon, MPharm, MSc<sup>3</sup>, Jean-Daniel Hecq, MPharm, MSc, PhD<sup>4</sup>, Jacques Jamart, MD<sup>5</sup>, Alain Dive, MD<sup>6</sup>; (1)Clinical Pharmacy, Cliniques Universitaire Mont-Godinne, Yvoir, Belgium; (2)Clinical Pharmacy Center, School of pharmacy, Catholic University of Louvain, Brussels, Belgium; (3)Clinical Pharmacy, Cliniques Universitaires de Mont-Godinne, Yvoir, Belgium; (4)Pharmacy, Cliniques Universitaires de Mont-Godinne, Yvoir, Belgium; (5)Unité de Biostatistique, Cliniques Universitaires de Mont-Godinne, Yvoir, Belgium; (6)Critical care unit, Cliniques Universitaires de Mont-Godinne, Yvoir, Belgium*

## Obstetrics and Gynaecology

176E. Spinal versus general anaesthesia for planned Caesarean section in pregnant healthy women.

*Gordana D. Vucic, MSc, Mirjana Kendrisic, MD, Prim; Health Centre Sremska Mitrovica, Sremska Mitrovica, Serbia and Montenegro*

## Oncology

177. The Role of Clinical Pharmacist in Detecting and Preventing Medication Errors in Cancer Chemotherapy.

*manal H. El Hamamsy, Ph.D, Nermin A.,Heba M.,Mohamed M. Abou- elsad,el zawahry,Al Azizi, MD, PhD, MD; faculty of pharmacy.Ain Shams University.Cairo Egypt, Cairo*

## Pediatrics

178F. Effect of computerized prescriber order entry with decision support on antibiotic errors in neonatal late onset sepsis.  
*Sandra S. Garner, Pharm.D.*, Toby H. Cox, Pharm.D., Michael G. Irving, MS, BS, Elizabeth G. Hill, Ph.D., Robin Bissinger, Ph.D., NNP, David J. Annibale, M.D.; Medical University of South Carolina, Charleston, SC

179. Impact of Having a Clinical Pharmacist in a Paediatric Intensive Care Unit.  
*Hoda M. Badran, M.S, clinical, pharmacy*, Wael S. Seleem, MD, Rasha Z. Al Anani, Bpharm; HMC, Doha, Qatar

### **Pharmaceutical Care**

180. Development and validation of a pharmaceutical care plan for patients with type 2 diabetes.  
*Dalal Al-Taweel, MPharm, MSc, MRPharmS<sup>1</sup>*, Steve Hudson, Professor<sup>2</sup>, Abdelmoneim A. Hussein, BPharm, MPharm, PhD<sup>3</sup>;  
(1)Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom;  
(2)Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0NR, United Kingdom;  
(3)Kuwait University, Kuwait City, Kuwait

### **Pharmacoepidemiology**

181. Adverse drug Reaction Documentation by Clinical Pharmacists in Riyadh City, Saudi Arabia.  
*Yousef Ahmed Alomi, Bsc., Msc., BCPS*, Naif Bakarman, Bsc. ; King Saud Medical Complex, Regional Drug and Poisoning Information Center, Riyadh, Saudi Arabia

### **PRN**

183. Highlighting the Ambulatory Care PRN.  
*Mitzi Wasik, Pharm.D., BCPS<sup>1</sup>*, Christina E. DeRemer, Pharm.D.<sup>2</sup>, Sheila L. Stadler, PharmD<sup>3</sup>, Alissa Smith, PharmD<sup>4</sup>, Sunny A. Linnebur, Pharm.D.<sup>5</sup>, Gloria R. Grice, Pharm.D.<sup>6</sup>, Jeanette L. Altavela, PharmD, BCPS<sup>7</sup>; (1)University of Illinois at Chicago, Chicago, IL; (2)Medical College of Georgia, Augusta, GA; (3)Kaiser Foundation Health Plan of Colorado, Aurora, CO; (4)South Carolina College of Pharmacy, Greenville, SC; (5)University of Colorado Health Sciences Center, School of Pharmacy, Denver, CO; (6)St. Louis College of Pharmacy, St. Louis, MO; (7)Greater Rochester Independent Practice Association, Rochester, NY

### **Rheumatology**

185. Pharmaceutical care for patients with rheumatoid arthritis on methotrexate: an extension of clinical pharmacy in an out-patient clinic.  
*Louise. A. Azzopardi, B.Pharm, (Hons), M.Phil, (Glas)<sup>1</sup>*, Steve Hudson, Professor<sup>2</sup>, Anthony Serracino Inglott, B.Pharm, PharmD<sup>3</sup>, Franco Camilleri, MD, MRCP<sup>4</sup>, Paul. J. Cassar, MD, MRCP<sup>4</sup>, Bernard Coleiro, MD, MRCP<sup>4</sup>, Karen Cassar, MD, MRCP<sup>4</sup>, Carmel Mallia, MD, MRCP<sup>5</sup>; (1)Clinical Pharmacy Section, Mater Dei Hospital, Msida, Malta; (2)Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0NR, United Kingdom; (3)Pharmacy Department, University of Malta, Msida, Malta; (4)Rheumatology Division, Department of Medicine, Mater Dei Hospital, Msida, Malta; (5)Department of Medicine, University of Malta, Msida, Malta

### **Women's Health**

186. Development and implementation of treatment protocols for the management of symptoms in pregnancy.  
*Lilian M. Azzopardi, BPharm, (Hons), MPhil, PhD*, Anthony Serracino-Inglott, BPharm, Pharm, D, Maurice Zarb-Adami, B, Pharm, PhD, Roberta Fenech, B, Pharm, (Hons); Department of Pharmacy, University of Malta, Msida, Malta

### **RESIDENTS AND FELLOWS RESEARCH IN PROGRESS**

These papers describe original research by residents and fellows in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoconomics, and pharmacoepidemiology in which the research is still ongoing.

### **ADR/Drug Interactions**

187. Vitamin D Levels and Statin-Induced Myopathy: A Retrospective Analysis.

*Jamie L. Killion, Pharm.D.*, Lauri Witt, Pharm.D., Monica G. Schaefer, Pharm.D.; Kansas City VA Medical Center, Kansas City, MO

188. Proton pump inhibitor contribution to cardiovascular events in users of clopidogrel.

*John T. Holmes, Pharm.D.*, Brooke Pugmire, Pharm.D., Rex Force, Pharm.D.; Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello, ID

189. Evaluation of agreement between the drug interaction probability score (DIPS) and Naranjo scale (NS) for drug interaction-induced ADRs in warfarin patients.

*Katherine M. Malloy, Pharm.D.*, Daniel A. Lewis, Pharm.D., BCPS, Kelly M. Smith, Pharm.D., BCPS, FASHP, FCCP, Douglas T. Steinke, PhD., George A. Davis, PharmD, BCPS; UKHealthCare, Lexington, KY

## **Adult Medicine**

190. Appropriate use of stress ulcer prophylaxis in general medicine patients.

*Jennifer R. Niemerg, Pharm.D.*<sup>1</sup>, Leah M. Nanne, Pharm.D., Candidate<sup>2</sup>, David S. Chun, Pharm.D., BCPS<sup>1</sup>; (1)St. Elizabeth's Hospital, Belleville, IL; (2)Southern Illinois University Edwardsville, School of Pharmacy, Edwardsville, IL

## **Ambulatory Care**

191. The impact of enoxaparin on INR in patients monitored by point-of-care device.

*Larissa N. Hall, Pharm.D.*, Amy N. Thompson, Pharm.D., BCPS, Kelly R. Ragucci, Pharm.D., FCCP, BCPS, CDE; MUSC Medical Center/South Carolina College of Pharmacy, Charleston, SC

192. Formulary conversion of ezetimibe/simvastatin to rosuvastatin: evaluation of a cost savings initiative.

*Augustus Hough IV, Pharm.D.*, Cherylyn Beckey, Pharm.D., BCPS, CDE, Julie Groppi, Pharm.D., CDE; Veterans Affairs Medical Center, West Palm Beach, FL

193. Evaluation of the incidence and risk factors of fenofibrate-associated nephrotoxicity.

*Rebecca L. Owens, PharmD, BCPS*<sup>1</sup>, Michael A. McKnight, BS<sup>2</sup>, Christopher R. Frei, PharmD, MSc, BCPS<sup>1</sup>, Laurajo Ryan, PharmD, MSc, BCPS<sup>1</sup>, John R. Downs, MD<sup>2</sup>, William D. Linn, PharmD<sup>3</sup>; (1)The University of Texas at Austin and The University of Texas Health Science Center at San Antonio, San Antonio, TX; (2)University of Texas Health Science Center San Antonio, San Antonio, TX; (3)University of the Incarnate Word, San Antonio, TX

## **Community Pharmacy Practice**

199. Impact of community pharmacy-based management of a targeted diabetic population.

*Mindy L. Jock, Pharm.D.*<sup>1</sup>, Teresa B. Klepser, Pharm.D.<sup>2</sup>, Jennifer Hagerman, Pharm.D.<sup>3</sup>, Michael Bouthillier, BSPHarm, Pharm.D.<sup>4</sup>, Donald G. Klepser, Ph.D., M.B.A.<sup>5</sup>; (1)ProMed Family Practice, Portage, MI; (2)Ferris State University, Portage, MI; (3)Ferris State University, Flint, MI; (4)Ferris State University, Grand Rapids, MI; (5)University of Nebraska Medical Center, Omaha, NE

200. Implementation and Evaluation of a Blood Pressure Monitoring Service in Grocery Store Chain Pharmacies.

Mindy B. Guerra, Pharm.D.<sup>1</sup>, Thane A. Kading, RPh<sup>2</sup>, Karen Farris, PhD., Professor<sup>3</sup>, *Jay D. Currie, PharmD*<sup>4</sup>; (1)University of Iowa/Hy-vee Pharmacy, Cedar Rapids, IA; (2)Hy-Vee, Cedar Rapids, IA; (3)University of Iowa, Iowa City, IA; (4)College of Pharmacy, The University of Iowa, Iowa City, IA

## **Education/Training**

204. Evaluation of a preceptor development program in a tertiary care health system.

*Heather Somand, PharmD*<sup>1</sup>, Dennis M. Gates, RPh, MS<sup>2</sup>; (1)Harper University Hospital, Detroit, MI; (2)Children's Hospital of Michigan, Detroit, MI

205. The biopharmaceutical industry: a survey of students' perceived knowledge and interest.

*Benjamin P. Exter, Pharm.D.*, James Scanlon, Pharm.D., Raymond Kim, Pharm.D., Hamdan Almas, Pharm.D., Michael Steinberg, Pharm.D., Courtney Jarvis, Pharm.D.; Massachusetts College of Pharmacy and Health Sciences, Worcester, MA

206. Meeting expectations for National Patient Safety Goal Requirement 3E: A health literacy focused patient education program.

*Kristin Tuiskula, Pharm.D.*<sup>1</sup>, Shannielle Danner, Pharm.D., Candidate<sup>2</sup>, Kelly Bennett, Pharm.D., Candidate<sup>2</sup>, Monina Lahoz, PhD<sup>2</sup>, Andrea Gorman, MS, RD, LDN<sup>1</sup>, George Abraham, MD, MPH<sup>1</sup>, Karyn Sullivan, RPh, MPH<sup>2</sup>; (1)St. Vincent Hospital, Worcester, MA; (2)Massachusetts College of Pharmacy and Health Sciences, Worcester, MA

207. Evaluation of Patient Education for Transdermal Fentanyl.

*Megan R. Stapleton, Pharm.D.*, Jolynn Sessions, Pharm.D., BCOP; Charles George VA Medical Center, Asheville, NC

## **Endocrinology**

208. Triple renin-angiotensin-aldosterone-system (RAAS) inhibition: safety and efficacy of angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), and direct renin inhibition combination therapy.

*Andrea N. Traina, Pharm.D.*<sup>1</sup>, Michael P. Kane, Pharm.D.<sup>1</sup>, Robert S. Busch, M.D.<sup>2</sup>, Gary Bakst, M.D.<sup>3</sup>, Jill M Abelseth, M.D.<sup>3</sup>, Robert A. Hamilton, Pharm.D.<sup>4</sup>; (1)Albany College of Pharmacy, Albany, NY; (2)The Endocrine Group, LLP, Albany, NY; (3)The Endocrine Group, Albany, NY; (4)Albany College of Pharmacy and Health Sciences, Albany, NY

209. Retrospective analysis of continuous subcutaneous insulin infusion therapy in type 2 diabetic patients and a survey assessing patient satisfaction with insulin pump therapy.

*Chad K. Gentry, PharmD*<sup>1</sup>, L. Brian Cross, PharmD<sup>1</sup>, Benjamin N. Gross, PharmD<sup>1</sup>, Joni C. Foard, PharmD<sup>1</sup>, Sherif Yacoub-Wasef, MD<sup>2</sup>, Emily Ham, RN<sup>2</sup>, Kim Nuss, PA-C<sup>2</sup>; (1)University of Tennessee / Holston Medical Group, Kingsport, TN; (2)Holston Medical Group, Kingsport, TN

## **Health Services Research**

210. Electronic and personal health record adoption in pharmacy practice in Nebraska.

*Kevin T. Fuji, Pharm.D.*<sup>1</sup>, Kimberly A. Galt, Pharm.D.<sup>1</sup>, Alexandra B. Serocca, B.A.<sup>2</sup>; (1)Creighton Health Services Research Program, Creighton University School of Pharmacy and Health Professions, Omaha, NE; (2)Creighton University School of Pharmacy and Health Professions, Omaha, NE

## **Medical Informatics**

218. Impact of an electronic risk factor assessment and medication order set on contrast induced nephropathy.

*Megan A. McKee, PharmD*, Pamela R. Maxwell, Pharm.D., Kay Green, RPh, Darrel W. Hughes, Pharm.D., Colleen Barthol, PharmD; University Health System, San Antonio, TX

## **Medication Safety**

219. What is the evidence for the FDA warning for intravenous haloperidol and QT interval prolongation ?.

*Carla Meyer-Masseti, MSc*, Christine M Cheng, PharmD, B Joseph Guglielmo, PharmD; University of California San Francisco, San Francisco, CA

220. Evaluation of an Anticoagulation Clinic Medication Reconciliation Process.

*Kade T. Birkeland, PharmD*, Lori Spellman, PharmD, David Parra, PharmD, BCPS; The Department of Veterans Affairs Medical Center, West Palm Beach, FL

221. Drug use evaluation of fondaparinux at a community teaching hospital.

*Rachelle M. Busby, Pharm.D.*, Ronald J. Campbell, Pharm.D., BCPS; UPMC St. Margaret, Pittsburgh, PA

## **Oncology**

222. Medication use evaluation of megestrol acetate in cancer patients.

*Stephanie V. Phan, Pharm.D.*, Patricia Rhee, Pharm.D.; West Palm Beach VA Medical Center, West Palm Beach, FL

## **Pediatrics**

223. Evaluation of antimicrobial prophylaxis in pediatric surgical patients.

*Pratish C. Patel, Pharm.D.*<sup>1</sup>, Kelley Lee, Pharm., D., BCPS<sup>2</sup>, Sandra Arnold, M.D., FRCPC<sup>1</sup>; (1)University of Tennessee / Le Bonheur Children's Medical Center, Memphis, TN; (2)LeBonheur Children's Medical Center, Memphis, TN

224. Survey of pediatric hospitals adoption of once daily aminoglycoside dosing.

*Dianna K. Proulx, Pharm.D.*, Melissa O'Neill, Pharm., D., Lindsay Lester, Pharm., D.; Huntsville Hospital, Huntsville, AL

225. Evaluation of therapeutic monitoring of once-daily gentamicin in preterm neonates based on serum creatinine concentrations.

*Andrea R. Chamberlain, PharmD*, Kendra C. Bosley, PharmD, Brian C. Yarberry, PharmD; Kosair Children's Hospital, Louisville, KY

### **Pharmacoeconomics/Outcomes**

226. Organizational and financial impact of centralized preparation of antineoplastic monoclonal antibodies in a French hospital.

*Baptiste Quélenec, Pharmacist, Resident*, Christelle Lemarignier, Pharmacist, Michèle Ancel, Pharmacist, Daniel Roncalez, Pharmacist; Hôpitaux Civils de Colmar, Colmar, France

227. Hospital Costs Associated with a Pharmacodynamic Based Clinical Pathway for Empiric Antibiotic Choice in Patients Infected with Ventilator Associated Pneumonia.

*Anthony M. Nicasio, Pharm.D.<sup>1</sup>*, Kathryn J. Eagye, MPH<sup>1</sup>, Effie L. Kuti, Pharm.D.<sup>2</sup>, David P. Nicolau, Pharm.D., FCCP, FIDSA<sup>1</sup>, Joseph L. Kuti, Pharm.D.<sup>1</sup>; (1)Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT; (2)University of Connecticut, School of Pharmacy, Storrs, CT

### **Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery**

228. Tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs.

*Jared L. Crandon, Pharm.D., BCPS*, Aryun Kim, Pharm.D., David P. Nicolau, Pharm.D., FCCP, FIDSA; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT

229. Cockcroft-Gault (CG) using ideal body weight (IBW) versus adjusted body weight (AdjBW) in obese patients.

*Marco R. Scipione, Pharm.D.*, Polina Lerner, Pharm.D., Boris Nogid, Pharm.D., BCPS, Robert DiGregorio, Pharm.D.; The Brooklyn Hospital Center, Brooklyn, NY

230. A comparison of gentamicin dosing strategies in neonates  $\leq 29$  weeks gestation.

*Keliana L. O'Mara, PharmD, BCPS<sup>1</sup>*, Peter Gal, PharmD, BCPS<sup>2</sup>, Christopher C. McPherson, PharmD<sup>1</sup>; (1)Women's Hospital of Greensboro, Greensboro, NC; (2)Greensboro Area Health Center, Greensboro, NC

231. An In Vitro Pharmacodynamic Model of a Human Simulated High Dose, Prolonged Infusion Meropenem Regimen against *Klebsiella* spp. producing the KPC Carbapenemase.

*Catharine C. Bulik, Pharm.D.*, Henry Christensen, BS, Peng Li, BS(Pharm), David P. Nicolau, Pharm.D., FCCP, FIDSA, Joseph L. Kuti, Pharm.D.; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT

### **Transplant/Immunology**

232. Evaluation of the effect of a transplant specialty pharmacy service line on renal allograft rejection.

*Nicole Kenyon, Pharm.D.*, Crystal Truax, Pharm.D., Sabrina Lee, Pharm.D., Michael Kelly, R.Ph., Lonnie Smith, Pharm.D.; University of Utah Hospitals and Clinics, Salt Lake City, UT

233. Valproate use in women of childbearing potential

*Christine D. Lee, PharmD*, Rex Force, PharmD and Brooke Pugmire, Pharm.D. Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello, ID

## **STUDENT SUBMISSIONS**

These papers describe original research by students in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology in which the research is still ongoing.

### **Infectious Diseases**

264. Risk factors associated with metronidazole failure in treating patients with *Clostridium difficile*-associated disease in a community hospital.

*Nadeje Aurubin, Pharm, D, Candidate<sup>1</sup>*, Vanthida Huang, PharmD, BSPHM<sup>2</sup>, NaaDede Badger, PharmD, BCPS<sup>3</sup>, Todd Parker, PharmD<sup>3</sup>; (1)Mercer University College of Pharmacy and Health Sciences, Atlanta, GA; (2)Department of Pharmacy Practice, Mercer University College of Pharmacy and Health Sciences, Atlanta, GA; (3)Piedmont Hospital, Atlanta, GA

## Neurology

275. Survey of risk factors for Osteoporosis among Epilepsy patients

*Marianna Fedorenko, Student<sup>1</sup>, Mary L. Wagner, M.S., Pharm.D.<sup>1</sup> and Brenda Y. Wu, M.D., Ph.D.<sup>2</sup>*

(1)Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, Piscataway, NJ

(2)UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ

## LATE BREAKERS

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

## ADR/Drug Interactions

297. Impact of acid suppression therapy on response to iron replacement for iron deficiency anemia

*Liza Barbarello-Andrews, PharmD and Cynthia DePiano, PharmD*

Rutgers, The State University of NJ and the University Medical Center at Princeton, Princeton, NJ

## Adult Medicine

299. Assessment of subcutaneous absorption of enoxaparin for deep vein thrombosis prophylaxis using anti-factor Xa level measurements in non-critically-ill mechanically-ventilated patients

*Angela O. Shogbon, Pharm.D.<sup>1</sup>, Steven B. Levy, Pharm.D., BCPS, CGP<sup>2</sup>, Wilfrid Herard, MD<sup>2</sup>, Maria Arias, RNC, BSN<sup>2</sup> and Henry Cohen, MS, Pharm.D., FCCM, BCPP, CGP<sup>3</sup>*

(1)Mercer University College of Pharmacy and Health Sciences, Decatur, GA

(2)Kingsbrook Jewish Medical Center, Brooklyn, NY

(3)Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University and Kingsbrook Jewish Medical Center, Brooklyn, NY

300. Characterization of thromboprophylaxis failures in bariatric surgery patients

*Pamela M. Moye, PharmD, BCPS<sup>1</sup>, Celio Burrowes, MD, FACS<sup>2</sup> and Teresa Pounds, PharmD, BCNSP<sup>2</sup>*

(1)Mercer University College of Pharmacy and Health Sciences, Atlanta, GA

(2)Atlanta Medical Center, Atlanta, GA

## Clinical Administration

302. Anticoagulation Process Improvement utilizing FMEA

*Shahnawaz Khan, BS, Haider Syed, MS and Saleem Ahmad, PhD*

Harlem Hospital Center, New York, NY

303. Compliance with SCIP antibiotic standards among hospitals in a group purchasing organization

*Scot E. Walker, PharmD, MS*

Amerinet, Inc, St. Louis, MO

## Education and Training

306. Preparation of pharmacy clerkship students for advanced pharmacy practice experiences

*Kellie L. Bennett, PharmD, BCPS<sup>1</sup>, Amy Lullo, RPh<sup>2</sup> and Susan Cornell, PharmD, CDE<sup>2</sup>*

(1)Sullivan University College of Pharmacy, Louisville, KY

(2)Midwestern University, Chicago College of Pharmacy, Downers Grove, IL

307. Comparison of students' perceptions of preparedness for an oral examination versus a written examination  
*Justine Gortney, PharmD, BCPS*, Lisa M. Lundquist, PharmD, BCPS and Phillip S. Owen, PharmD, BCPS  
Mercer University, Atlanta, GA

308. Therapeutic education for stroke hypertensive patients: preliminary results of a pilot study  
*Beaussier Hélène, Ms<sup>1</sup>*, Rouault Anne, Dr<sup>1</sup>, Houot Mélanie, Ms<sup>1</sup>, Bézie Yvonnick, Dr<sup>1</sup> and Zuber Mathieu, Pr<sup>2</sup>  
(1)Department of Pharmacy Groupe Hospitalier Paris Saint Joseph, Paris, France  
(2)Department of Neurology Groupe Hospitalier Paris Saint Joseph, Paris, France

309. Impact of a student-supported pharmacy assessment program on venous thromboembolism assessment and prophylaxis rates in hospitalized patients  
*Laura E. Butkivich, Pharm.D.<sup>1</sup>*, Zachary A. Stacy, Pharm.D., BCPS<sup>2</sup>, Michael W. Daly, Pharm.D., BCPS<sup>2</sup>, Way Y. Huey, Pharm.D., FCCM, BCPS<sup>3</sup> and Charles T. Taylor, Pharm.D., BCPS<sup>4</sup>  
(1)University of Missouri Hospital and Clinics, Columbia, MO  
(2)St. Louis College of Pharmacy, St. Louis, MO  
(3)St. Luke's Hospital, Chesterfield, MO  
(4)University of Minnesota College of Pharmacy, Minneapolis, MN

## Gastroenterology

310. Protective effects of *Nigella sativa* oil on antituberculous drug combination- induced hepatotoxicity in rats  
Nur Sener, M.Sc<sup>1</sup>, Fikret V. Izzettin, Prof.<sup>2</sup>, Ozlem Ozakpinar, M.Sc<sup>1</sup>, *Murat B. Rabus, M.D.<sup>3</sup>*, Betül Okuyan, MSc<sup>2</sup>, Mesut Sancar, Ph.D.<sup>2</sup>, Elcin Yorukoglu, Pharm<sup>2</sup> and Fikriye Uras, Prof<sup>1</sup>  
(1)Marmara University Faculty of Pharmacy, Biochemistry Department, Istanbul, Turkey  
(2)Marmara University Faculty of Pharmacy, Clinical Pharmacy Department, Istanbul, Turkey  
(3)Kosuyolu Heart and Research Hospital, Cardiovascular Surgery Department, Istanbul, Turkey

## Medication Safety

316E. Improving accessibility, effectiveness, safety and work life with pharmacy technician on the patient care units  
*T.H. Diem Vo, B.Pharm., M.Sc., MBA*, Alain Biron, N. PhD(c), Patricia Lefebvre, B. Pharm., M. Sc., FCSHP and Linda Ward, M. Sc. (A)  
McGill University Health Centre, Montreal, QC, Canada

317E. Prespective experience in the Italian Piedmont network for oncology of complex cooperation among oncologists, pharmacists and nurses in a modern oncology unit  
*Elena Giubellino, PhD*, Cristiano Oliva, MD and Alessandro Comandone, MD  
Gradenigo Hospital, Turin, Italy

318. Compounding Project: Calcium Levofolinate  
Anna Bianca Calzona, Daniela Checquolo, Simona Ferraiuolo, Giovanni Guarany, PHARMACY, Gerardo Miceli Sopo, *Grazia Mingolla*, and Roberto Tazza.  
Sandro Pertini Hospital, Rome, Italy

319. HEALTH Technology Assessment:Trastuzumab  
Anna Bianca Calzona, Daniela Checquolo, Simona Ferraiuolo, Giovanni Guarany, PHARMACY, Gerardo Miceli Sopo, *Grazia Mingolla*, and Roberto Tazza.  
Sandro Pertini Hospital, Rome, Italy

## Patient Care

320. Diabetic patients' knowledge of therapeutic goals, adherence to medications and life style modifications in Kuwait  
*Abdelmoneim Awad Hussein, BPharm, MPharm, PhD* and Hala Dalle, B.Pharm  
Faculty of Pharmacy, Kuwait University, Kuwait City, Kuwait

### **Pediatrics**

321. Efficacy and safety of omalizumab added to optimized asthma care in children with inadequately controlled allergic asthma

B. Lanier Jr., MD<sup>1</sup>, T. Bridges, MD<sup>2</sup>, M. Kulus, MD<sup>3</sup>, A. FowlerTaylor, RPh<sup>4</sup>, M. Blogg, MD<sup>5</sup>, R. Maykut, MD<sup>4</sup>, *M. Massanari, PharmD<sup>4</sup>* and P. Jimenez, MD<sup>4</sup>

(1)University of North Texas, Fort Worth, TX

(2)Georgia Pollens Clinical Research Centers Inc, Albany, GA

(3)Medical University of Warsaw, Warsaw, Poland

(4)Novartis Pharmaceuticals Corporation, East Hanover, NJ

(5)Novartis Horsham Research Centre, Horsham, United Kingdom

### **Pharmacokinetics/Pharmacodynamics**

324E. Quality of life assessment in diabetic patients attending outpatient clinic in a tertiary health care facility  
*Ehijie Enato, PhD<sup>1</sup>*, Ephraim Ekweanua, PharmD<sup>2</sup>, Azuka C. Oparah, PhD<sup>1</sup>, Michael E. Arigbe-Osula, PharmD<sup>1</sup> and Ochuwa E. Aghomo, MPharm<sup>1</sup>

(1)Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, University of Benin, Benin City, Nigeria

(2)Federal Medical Center, Asaba, Asaba, Nigeria

325. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults

*Mary Haffey, RPh*, Mary Buckwalter, MS, Pinggao Zhang, PhD, Robert Homolka, MS, Patrick Martin, MD, Ken Lasseter, MD and James Ermer, MS

Shire Development Inc., Wayne, PA

### **Psychiatry**

326. Systematic review: treatment of mental health disorders in the Arab countries

*Soumana A. Nasser, Pharm.D.*

School of Pharmacy, Lebanese American University, Beirut, Lebanon